Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cam161533
- Development stage
- Preclinical
- Lead developer
- University of Minnesota
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
cam161533 is a Tri-Specific Killer Cell Engager (TriKE) designed for the treatment of acute myeloid leukemia (AML). It is a recombinant fusion protein that simultaneously targets CD16 on natural killer (NK) cells and CD33 on AML cells, while incorporating an interleukin-15 (IL-15) moiety to promote NK cell expansion, persistence, and activation. By bridging NK cells to tumor cells and providing a localized cytokine signal, cam161533 enhances NK cell-mediated cytotoxicity against myeloid malignancies. It is currently being evaluated in preclinical studies, often in combination with other immunotherapies such as IL-1RAP-targeted CAR-NK cells, to overcome chemotherapy resistance in relapsed or refractory AML.
- Other names
- cam161533 TriKEcam-161533 TriKEcam 161533 TriKECD16-IL15-CD33 TriKECD-16-IL15-CD33 TriKECD 16-IL15-CD33 TriKE
02
Targets
CD33 (Myeloid cell surface antigen CD33)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)NKG2D (Natural killer group 2 member D receptor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on cam161533.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cam161533.